<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="627">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02378792</url>
  </required_header>
  <id_info>
    <org_study_id>PINS-012</org_study_id>
    <nct_id>NCT02378792</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Vagus Nerve Stimulation for Treatment of Refractory Epilepsy</brief_title>
  <acronym>VNSRE</acronym>
  <official_title>The Clinical Research on TsingHua Vagus Nerve Stimualtor for Treatment of Refractory Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Pins Medical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Pins Medical Co., Ltd</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the long-term clinical effectiveness and safety of the PINS vagus nerve stimulator
      to patients with refractory epilepsy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes in seizure frequency from baseline to the seizure count evaluvation period 6 month</measure>
    <time_frame>6 month of stimulation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in seizure frequency from baseline to the seizure count evaluvation period</measure>
    <time_frame>1,3,6,12 months of stimulation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in seizure frequency from baseline to 1,3,6,12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Quality of Life in Epilepsy-31 (QOLIE-31) Score in Patients With Baseline &amp; at Least One Post-baseline QOLIE Assessment</measure>
    <time_frame>Mean change from baseline QOLIE-31 Overall Score at 1,3,6,12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>QOLIE-31 contains 7 multi-item scales that tap the following health concepts:overall quality of life, emotional well-being, social functioning, energy/fatigue, worry about seizure,cognitive functioning,medication effects. Range of values 0-100. Higher scores reflect better quality of life; lower ones, worse quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Number of Anti-epileptic Drugs Prescribed</measure>
    <time_frame>At 1,3,6 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in Anti-Epileptic Drugs (AEDs) in patients with less then a 50% reduction in seizures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change fron Basline in the Engel and McHugh description</measure>
    <time_frame>At 1,3,6 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Refractory Epilepsy</condition>
  <arm_group>
    <arm_group_label>Vagus Verve Stimulation is on</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Vagus Verve Stimulation is off</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vagus Nerve Stimulation</intervention_name>
    <description>Vagus Nerve Stimulator</description>
    <arm_group_label>Vagus Verve Stimulation is on</arm_group_label>
    <arm_group_label>Placebo Vagus Verve Stimulation is off</arm_group_label>
    <other_name>PINS Stimulator System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age 6-60.

          2. Having tried at least two appropriate anti-epileptic drugs (AEDs) tested to tolerance
             or to blood levels at upper end of the target range of which at least 2 have been
             tolerated at normal dose.

          3. at least 6 seizures per month.

          4. in good health except epilepsy.

          5. to with normal MMSE score

          6. patients or his(her) familyscould understand this method and sign the informed
             consent 7）Patients with good compliance and could complete postoperative follow-up.

        Exclusion Criteria:

          1. results of MRI remind epilepsy caused by intracranial space-occupying lesions.

          2. the vagus nerve lesion and damage

          3. tumor, cardiopulmonary anomaly, progressive neurological diseases, asthma，mental
             disease，peptic ulcer，diabetes Type 1，bad health etc, and other surgical
             contraindication.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jia Fumin, PhD</last_name>
    <phone>+86 010-59361265</phone>
    <email>pins_medical@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Luming, PhD</last_name>
    <phone>+86 010-60736388</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianguo Zhang, MD</last_name>
      <phone>010-67096611</phone>
      <email>Limuxin2011@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first hospital of jilin university</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kan Xu, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jiqing Qiu</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The general of shenyang military</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guobiao Liang, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Guanqian Yuan</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Qilu hospital of shandong university</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shujun Xu, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Wenhua Zhang</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The second affiliated hospital zhejiang university school of medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiming FU, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Junming Zhu</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>October 12, 2015</lastchanged_date>
  <firstreceived_date>February 27, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PINS VNS Refractory Epilepsy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
